1. Analyst View 2. Research Methodology 3. Bi-Specific Antibodies – An Introduction 4. Global Bi-Specific Antibodies Market Outlook to 2022 4.1 BLINCYTO 4.2 Hemlibra 4.3 Removab 5. Bi-Specific Antibodies Pipeline Analysis 5.1 By Clinical Phase 5.2 By Indication 5.3 By Technology 6. Market Dynamics 6.1 Drivers 6.1.1 Rising Global Cancer Epidemics 6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs 6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy 6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies 6.2 Challenges 6.2.1 Production Hurdles in Bi-Specific Antibodies Development 6.2.2 Regulatory Challenges 7. Current Status of Major Bi-Specific Antibodies in Pipeline 7.1 BLINCYTO/Blinatumomab – Amgen Inc. 7.2 ABT-122 – AbbVie Inc. 7.3 MCLA-128 – Merus N.V. 7.4 ALX-0761/M1095 - Ablynx 7.5 MGD006/S80880 – MacroGenics, Inc. 7.6 ZW25 – Zymeworks Inc. 8. Trends and Developments 8.1 Bi-specific Antibody Application for Tumor Therapy 8.2 Bi-specific Antibodies Development Against Myeloma 8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics 8.4 B-specific Antibody Development against Multiple Ebola viruses 9. Strategic Collaborations in the Bi-Specific Antibodies Industry 10. Competitive Assessment 10.1 Amgen Inc. 10.2 F. Hoffman La Roche Ltd. 10.3 AbbVie Inc. 10.4 OncoMed Pharmaceuticals, Inc. 10.5 Glenmark Pharmaceuticals Limited 10.6 Xencor, Inc. 10.7 MacroGenics, Inc. 10.8 Aptevo Therapeutics Inc. 10.9 Ligand Pharmaceuticals, Inc. 10.10 Regeneron Pharmaceuticals, Inc. 10.11 Fresenius SE & Co. KGaA 10.12 Merus N.V.

List of Tables: Table 4-1: Global - Potential Patients for BLINCYTO (2017) Table 4-2: Global - Potential Patients for BLINCYTO (2020) Table 4-3: Global - Major Ongoing Trials for BLINCYTO Table 5-1: Global - Major Bi-Specific Antibodies in Pipeline Table 9-1: Global - Major Strategic Collaborations in the Bi-Specific Antibodies Industry Table 10-1: Top Companies by Bi-Specific Antibodies in Pipeline Table 10-2: Amgen Inc. - Product Portfolio Table 10-3: Amgen Inc. - Major Bi-Specific Antibodies in Pipeline Table 10-4: Amgen Inc. - Key Financials (Million US$), 2014-2016 Table 10-5: F. Hoffman La Roche Ltd. - Major Bi-Specific Antibodies in Pipeline Table 10-6: F. Hoffman La Roche Ltd. - Key Financials (Million US$), 2014-2016 Table 10-7: AbbVie Inc. - Major Bi-Specific Antibodies in Pipeline Table 10-8: AbbVie Inc. - Key Financials (Million US$), 2014-2016 Table 10-9: OncoMed Pharmaceuticals, Inc. - Major Bi-Specific Antibodies in Pipeline Table 10-10: OncoMed Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016 Table 10-11: Glenmark Pharmaceuticals Limited - Major Bi-Specific Antibodies in Pipeline Table 10-12: Glenmark Pharmaceuticals Limited - Key Financials (Million US$), FY2015-FY2017 Table 10-13: Xencor, Inc. - Major Bi-Specific Antibodies in Pipeline Table 10-14: Xencor, Inc. - Key Financials (Million US$), 2014-2016 Table 10-15: MacroGenics, Inc. - Major Bi-Specific Antibodies in Pipeline Table 10-16: MacroGenics, Inc. - Key Financials (Million US$), 2014-2016 Table 10-17: Aptevo Therapeutics - Major Bi-Specific Antibodies in Pipeline Table 10-18: Aptevo Therapeutics Inc. - Key Financials (Million US$), 2015-2016 Table 10-19: Ligand Pharmaceuticals, Inc. - Major Bi-Specific Antibodies in Pipeline Table 10-20: Ligand Pharmaceuticals, Inc. - Key Financials (Million US$), 2014-2016 Table 10-21: Regeneron Pharmaceuticals, Inc. - Major Bi-Specific Antibodies in Pipeline Table 10-22: Regeneron Pharmaceuticals, Inc. - Key Financials (Million US$), 2015-2017 Table 10-23: Fresenius SE & Co. KGaA - Product Portfolio Table 10-24: Fresenius SE & Co. KGaA - Key Financials (Million US$), 2014-2016 Table 10-25: Merus N.V. - Major Bi-Specific Antibodies in Pipeline List of Figures: Figure 3-1: Bi-Specific Antibodies - Mechanism of Action Figure 4-1: Global - Bi-Specific Antibodies Market (Million US$), 2016-2022 Figure 4-2: Global - BLINCYTO Sales (Million US$), 2016 & 2017 Figure 5-1: Global - Bi-Specific Antibodies Pipeline by Clinical Phase (%), 2017 Figure 5-2: Global - Bi-Specific Antibodies Pipeline by Indication (%), 2017 Figure 5-3: Global - Bi-Specific Antibodies Pipeline by Technology (%), 2017 Figure 6-1: Global - Cancer & Other Non-Communicable Disease Epidemics (%), 2016 Figure 10-1: Amgen Inc. - Breakup of Revenue by Geography (%), 2016 Figure 10-2: F. Hoffman La Roche Ltd. - Breakup of Group Sales by Business Segments (%), 2016 Figure 10-3: F. Hoffman La Roche Ltd. - Breakup of Group Sales by Geography (%), 2016 Figure 10-4: AbbVie Inc. - Breakup of Net Revenues by Geography (%), 2016 Figure 10-5: Glenmark Pharmaceuticals Limited - Breakup of Revenue by Geography (%), FY2017 Figure 10-6: Xencor, Incl. - Breakup of Revenue by Product Programs (%), 2016 Figure 10-7: Ligand Pharmaceuticals, Inc. - Breakup of Revenue by Operations (%), 2016 Figure 10-8: Ligand Pharmaceuticals, Inc. - Breakup of Royalty Revenue by Program (%), 2016 Figure 10-9: Ligand Pharmaceuticals, Inc. - Breakup of Material Sales by Use (%), 2016 Figure 10-10: Fresenius SE & Co. KGaA - Breakup of Sales by Business Segments (%), 2016 Figure 10-11: Fresenius SE & Co. KGaA - Breakup of Sales by Geography (%), 2016